查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1503313

到 2030 年生技药品合约开发和製造组织 (CDMO) 市场预测：按产品、服务、类型、最终用户和地区进行的全球分析

Biologics Contract Development and Manufacturing Organization Market Forecasts to 2030 - Global Analysis By Product, Service (Contract Manufacturing Organization and Contract Research Organization ), Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 预测，2024 年全球生技药品合约开发和製造组织（CDMO）市场规模将达到 145.4 亿美元，预测期内复合年增长率为 14.9%，到 2030 年将达到 334.5 亿美元。

单株抗体、疫苗、细胞和基因疗法以及重组蛋白等生物产品是在称为合约生技药品开发和製造组织 (CDMO) 的专业服务提供者的协助下开发和製造的。 CDMO 在细胞株开发、製程优化、分析测试和大规模生产等领域拥有丰富的经验，这使得这些组织对于生物製药产业至关重要。此外，透过与 CDMO 合作，生物製药公司可以降低成本、加快产品开发并更好地应对复杂的法规环境。

根据国际製药工程学会 (ISPE) 的说法，合约生技药品开发和受託製造厂商(CDMO) 对製药业至关重要，它们提供必要的服务，促进复杂生物製药。

人们对生技药品的兴趣日益浓厚

世界各地糖尿病、癌症和自体免疫疾病等慢性疾病的增加需要更有效和强化的治疗。生技药品因其高特异性和有效性而成为首选治疗选择。对生物製药日益增长的需求促使製药公司寻求 CDMO，因为它们拥有高效能满足其生产需求的专业知识。此外，人口老化和生物技术的发展正在刺激CDMO市场的稳定成长。

营运成本过高

生产生技药品的高营运成本是生技药品合约开发和製造组织（CDMO）市场面临的主要障碍之一。製造生技药品涉及复杂且成本高昂的步骤，包括先进的细胞培养技术、精製技术和严格的品管措施。对专业设施、高素质工人和最尖端科技的需求进一步增加了成本。此外，为了遵守法规和行业标准，CDMO 必须在设备和基础设施方面进行大量资本投资，这可能非常昂贵。

利用尖端製造技术

自动化、连续生物加工和一次性系统等现代製造技术为 CDMO 提供了提高产品品质和业务效率的重要机会。透过降低生产成本和提高扩充性，这些技术还可以降低污染风险。此外，透过利用这些创新，CDMO 可以增强其竞争优势并应对不断增长的优质生技药品市场。

熟练劳动力不足；

生技药品产业需要高技能的专业人员，包括细胞生物学、生物製程工程和监管事务方面的专家。然而，全球范围内缺乏具备必要知识和经验的专家来支持生技药品的发现和生产。 CDMO 无法吸引和留住熟练员工可能会抑制其扩展和更有效营运的能力。此外，为了吸引和留住顶尖人才，CDMO 必须提供有竞争力的薪资、培训计画和职涯发展机会。这是因为对技术工人的竞争非常激烈。

COVID-19 的影响：

由于 COVID-19 大流行，生技药品合约开发和製造组织 (CDMO) 市场经历了巨大的成长和变化。对疫苗、治疗方法和诊断工具的迫切需求催生了对 CDMO 服务的前所未有的需求，从而加快了生产进度并提高了製造能力。此外，COVID-19 疫苗和治疗方法的快速开发和广泛生产在很大程度上是透过 CDMO 实现的，这凸显了它们在生物製药供应链中的重要性。

生技药品产业预计将在预测期内成为最大的产业

生技药品产业在生技药品合约开发和製造组织（CDMO）市场中占据最大的市场占有率。生技药品包括多种复杂药物，包括重组蛋白、细胞和基因疗法、疫苗和单株抗体。由于慢性病盛行率的上升以及对个人化和标靶治疗的需求不断增长，生物製药市场正在扩大。此外，製药公司正在大力投资生技药品的开发和商业化，因为它们比传统小分子药物具有显着的治疗益处。

契约製造组织（CMO）产业预计在预测期内复合年增长率最高

在生技药品合约开发和製造组织（CDMO）市场中，受託製造厂商（CMO）细分市场通常表现出最高的复合年增长率。 CMO 是为生物製药提供端到端製造服务的专家，包括製程开发、放大和商业製造。此外，由于对生技药品的需求不断增加、製造流程复杂以及对专业知识的需求，製药公司正在将製造委託给 CMO。

比例最高的地区：

北美通常占据生技药品合约开发和製造组织（CDMO）市场的最大份额。许多因素促成了该地区的优势，包括蓬勃发展的生物製药产业、最先进的医疗设施、强大的法规环境以及高素质的劳动力。此外，北美拥有大量生物技术和製药公司以及着名的学术和研究机构，为生技药品的开发和製造创造了一个充满活力的生态系统。

复合年增长率最高的地区：

亚太地区的生技药品合约开发和製造组织 (CDO) 市场的复合年增长率通常最高。生物製药公司外包的增加、医疗保健基础设施投资的增加以及中国、印度和韩国等国家生物製药製造能力的增加是推动这一增长的因素。此外，有利的政府政策、监管改革和支持生物技术创新的倡议进一步增强了该地区对 CDMO 的吸引力。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第四章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章按产品分類的全球生技药品合约开发和製造组织 (CDMO) 市场

  • 生物相似药
  • 生物製药
    • 反义和分子治疗
    • 重组蛋白
    • 疫苗
    • 单复製
      • 基于蛋白质的
      • 诊断
      • 治疗性的
  • 其他产品

第六章全球生技药品合约开发与製造组织（CDMO）市场：依服务分类

  • 契约製造组织 (CMO)
  • 研究机构（CRO）

第七章全球生技药品合约开发与製造组织（CDMO）市场：按类型

  • 哺乳动物的
  • 非哺乳动物（微生物）
  • 病毒载体
  • 其他类型

第八章最终用户的全球生技药品合约开发和製造组织 (CDMO) 市场

  • 生技公司
  • 生物製药公司
  • 其他最终用户

第 9 章按地区分類的全球生技药品合约开发和製造组织 (CDMO) 市场

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Samsung Biologics
  • Boehringer Ingelheim Group
  • Sandoz Biopharmaceuticals（Novartis AG）
  • Parexel International Corporation
  • Fujifilm Diosynth Biotechnologies USA Inc.
  • AbbVie Contract Manufacturing
  • Lonza Group
  • Binex Co. Limited
  • Rentschler Biotechnologies
  • Toyobo Co. Limited
  • AGC Biologics
  • PRA Health Sciences
  • Catalent Inc
  • Wuxi Biologics
  • JRS Pharma
Product Code: SMRC26479

According to Stratistics MRC, the Global Biologics Contract Development and Manufacturing Organization (CDMO) Market is accounted for $14.54 billion in 2024 and is expected to reach $33.45 billion by 2030 growing at a CAGR of 14.9% during the forecast period. Biological products, such as monoclonal antibodies, vaccines, cell and gene therapies, and recombinant proteins, are developed and manufactured with the assistance of specialized service providers known as biologics contract development and manufacturing organizations, or CDMOs. Because they offer experience in fields like cell line development, process optimization, analytical testing, and large-scale production, these organizations are vital to the biopharmaceutical sector. Moreover, biopharma companies can cut costs, expedite product development, and more skillfully navigate complex regulatory environments by collaborating with CDMOs.

According to the International Society for Pharmaceutical Engineering (ISPE), Biologics Contract Development and Manufacturing Organizations (CDMOs) are vital to the pharmaceutical industry, providing essential services that enable the development, scale-up, and commercialization of complex biological products.

Market Dynamics:

Driver:

Growing interest in biologics

The need for more efficient and focused treatments is being driven by the rising global burden of chronic diseases like diabetes, cancer, and autoimmune disorders. Biologics are a preferred option for treatment because of their high specificity and efficacy. The increasing demand for biologics has led pharmaceutical companies to turn to CDMOs for their expertise in meeting production needs in an efficient manner. Additionally, this demand is further fueled by the aging population and biotechnology developments, which are driving the CDMO market's steady growth.

Restraint:

Excessive costs of operations

The high operating costs of producing biologics are one of the main obstacles facing the biologics Contract Development and Manufacturing Organization (CDMO) market. Complex and costly procedures, such as advanced cell culture techniques, purification techniques, and strict quality control measures, are involved in the manufacturing of biologics. Costs are further increased by the requirement for specialized facilities, highly qualified workers, and cutting-edge technologies. Furthermore, to comply with regulations and industry standards, CDMOs have to make large capital expenditures on equipment and infrastructure, which can be very expensive.

Opportunity:

Utilizing cutting-edge manufacturing technologies

Modern manufacturing techniques like automation, continuous bioprocessing, and single-use systems offer CDMOs great chances to improve both the quality of their output and operational efficiency. By lowering production costs and increasing scalability, these technologies can also lower the risk of contamination. Moreover, CDMOs can reinforce their competitive advantage and satisfy the increasing market for superior biologics by putting these innovations to use.

Threat:

Insufficiently skilled workforce

A highly skilled and specialized workforce is needed in the biologics industry, including experts in cell biology, bioprocess engineering, and regulatory affairs. Nonetheless, there is a dearth of professionals with the knowledge and experience needed to assist in the creation and production of biologics throughout the world. The inability of CDMOs to attract and retain skilled staff may impede their ability to expand and operate more efficiently. Additionally, in order to attract and retain top talent, CDMOs must provide competitive salaries, training programs, and opportunities for career development. This is because there is fierce competition for skilled workers.

Covid-19 Impact:

The market for biologics contract development and manufacturing organizations (or CDMOs) has seen tremendous growth and change as a result of the COVID-19 pandemic. An unprecedented demand for CDMO services resulted from the pressing need for vaccines, treatments, and diagnostic tools, which sped up production schedules and increased manufacturing capacity. Furthermore, the rapid development and widespread manufacturing of COVID-19 vaccines and treatments were made possible in large part by CDMOs, underscoring the significance of these organizations in the biopharmaceutical supply chain.

The Biologics segment is expected to be the largest during the forecast period

In the biologics contract development and manufacturing organization (CDMO) market, the biologics segment has the largest market share. Biologics comprise a broad spectrum of intricate medicinal items, such as recombinant proteins, cell and gene therapies, vaccines, and monoclonal antibodies. The market for biologics has expanded due to the rising incidence of chronic illnesses and the rising need for individualized and targeted treatments. Moreover, pharmaceutical companies have made significant investments in the development and commercialization of biologics due to their significant therapeutic advantages over traditional small-molecule drugs.

The Contract Manufacturing Organization (CMO) segment is expected to have the highest CAGR during the forecast period

In the biologics contract development and manufacturing organization (CDMO) market, the contract manufacturing organization (CMO) segment usually shows the highest CAGR. CMOs are experts in offering biopharmaceutical products end-to-end manufacturing services, encompassing process development, scaling up, and commercial production. Additionally, pharmaceutical companies outsource manufacturing to CMOs due to the growing demand for biologics, complex manufacturing processes, and the requirement for specialized expertise.

Region with largest share:

In the biologics contract development and manufacturing organization (CDMO) market, North America typically holds the largest share. Numerous elements contribute to the region's dominance, such as a thriving biopharmaceutical sector, state-of0-the-art healthcare facilities, a solid regulatory environment, and a highly qualified labour force. Furthermore, a thriving ecosystem for the development and production of biologics is fostered by the large number of biotech and pharmaceutical companies, as well as eminent academic and research institutions located in North America.

Region with highest CAGR:

In the market for biologics contract development and manufacturing organizations (CDOs), the Asia-Pacific region usually shows the highest CAGR. Increasing outsourcing among biopharmaceutical companies, growing investments in healthcare infrastructure and growing biopharmaceutical manufacturing capabilities in nations like China, India, and South Korea are some of the factors driving this growth. Moreover, the region's appeal to CDMOs is further enhanced by advantageous government policies, regulatory reforms, and initiatives to support biotech innovation.

Key players in the market

Some of the key players in Biologics Contract Development and Manufacturing Organization (CDMO) market include Samsung Biologics, Boehringer Ingelheim Group, Sandoz Biopharmaceuticals (Novartis AG), Parexel International Corporation, Fujifilm Diosynth Biotechnologies USA Inc., AbbVie Contract Manufacturing, Lonza Group, Binex Co. Limited, Rentschler Biotechnologies, Toyobo Co. Limited, AGC Biologics, PRA Health Sciences, Catalent Inc, Wuxi Biologics and JRS Pharma.

Key Developments:

In May 2024, AbbVie and Gilgamesh Pharmaceuticals have announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in psychiatry and Gilgamesh's innovative research platform to discover novel neuroplastogens.

In April 2024, FUJIFILM Diosynth Biotechnologies, a global leading contract development and manufacturing organization (CDMO), announced that it will expand its large-scale cell culture manufacturing facility currently under construction with a $1.2 billion investment from FUJIFILM Corporation.

In February 2024, Samsung Biologics, a global contract development and manufacturing organization (CDMO), has signed a partnership agreement with LegoChem Biosciences, a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs.

Products Covered:

  • Biosimilars
  • Biologics
  • Other Products

Services Covered:

  • Contract Manufacturing Organization (CMO)
  • Contract Research Organization (CRO)

Types Covered:

  • Mammalian
  • Non-Mammalian (Microbial)
  • Viral Vector
  • Other Types

End Users Covered:

  • Biotechnology Companies
  • Biopharmaceutical Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, By Product

  • 5.1 Introduction
  • 5.2 Biosimilars
  • 5.3 Biologics
    • 5.3.1 Antisense and Molecular Therapy
    • 5.3.2 Recombinant Proteins
    • 5.3.3 Vaccines
    • 5.3.4 Monoclonal
      • 5.3.4.1 Protein-Based
      • 5.3.4.2 Diagnostic
      • 5.3.4.3 Therapeutic
  • 5.4 Other Products

6 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, By Service

  • 6.1 Introduction
  • 6.2 Contract Manufacturing Organization (CMO)
  • 6.3 Contract Research Organization (CRO)

7 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, By Type

  • 7.1 Introduction
  • 7.2 Mammalian
  • 7.3 Non-Mammalian (Microbial)
  • 7.4 Viral Vector
  • 7.5 Other Types

8 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, By End User

  • 8.1 Introduction
  • 8.2 Biotechnology Companies
  • 8.3 Biopharmaceutical Companies
  • 8.4 Other End Users

9 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Samsung Biologics
  • 11.2 Boehringer Ingelheim Group
  • 11.3 Sandoz Biopharmaceuticals (Novartis AG)
  • 11.4 Parexel International Corporation
  • 11.5 Fujifilm Diosynth Biotechnologies USA Inc.
  • 11.6 AbbVie Contract Manufacturing
  • 11.7 Lonza Group
  • 11.8 Binex Co. Limited
  • 11.9 Rentschler Biotechnologies
  • 11.10 Toyobo Co. Limited
  • 11.11 AGC Biologics
  • 11.12 PRA Health Sciences
  • 11.13 Catalent Inc
  • 11.14 Wuxi Biologics
  • 11.15 JRS Pharma

List of Tables

  • Table 1 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biosimilars (2022-2030) ($MN)
  • Table 4 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics (2022-2030) ($MN)
  • Table 5 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Antisense and Molecular Therapy (2022-2030) ($MN)
  • Table 6 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Recombinant Proteins (2022-2030) ($MN)
  • Table 7 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Vaccines (2022-2030) ($MN)
  • Table 8 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Monoclonal (2022-2030) ($MN)
  • Table 9 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other Products (2022-2030) ($MN)
  • Table 10 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service (2022-2030) ($MN)
  • Table 11 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Manufacturing Organization (CMO) (2022-2030) ($MN)
  • Table 12 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Research Organization (CRO) (2022-2030) ($MN)
  • Table 13 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Type (2022-2030) ($MN)
  • Table 14 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Mammalian (2022-2030) ($MN)
  • Table 15 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Non-Mammalian (Microbial) (2022-2030) ($MN)
  • Table 16 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Viral Vector (2022-2030) ($MN)
  • Table 17 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 18 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2022-2030) ($MN)
  • Table 19 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biotechnology Companies (2022-2030) ($MN)
  • Table 20 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biopharmaceutical Companies (2022-2030) ($MN)
  • Table 21 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 22 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2022-2030) ($MN)
  • Table 23 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Product (2022-2030) ($MN)
  • Table 24 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biosimilars (2022-2030) ($MN)
  • Table 25 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics (2022-2030) ($MN)
  • Table 26 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Antisense and Molecular Therapy (2022-2030) ($MN)
  • Table 27 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Recombinant Proteins (2022-2030) ($MN)
  • Table 28 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Vaccines (2022-2030) ($MN)
  • Table 29 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Monoclonal (2022-2030) ($MN)
  • Table 30 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other Products (2022-2030) ($MN)
  • Table 31 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service (2022-2030) ($MN)
  • Table 32 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Manufacturing Organization (CMO) (2022-2030) ($MN)
  • Table 33 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Research Organization (CRO) (2022-2030) ($MN)
  • Table 34 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Type (2022-2030) ($MN)
  • Table 35 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Mammalian (2022-2030) ($MN)
  • Table 36 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Non-Mammalian (Microbial) (2022-2030) ($MN)
  • Table 37 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Viral Vector (2022-2030) ($MN)
  • Table 38 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 39 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2022-2030) ($MN)
  • Table 40 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biotechnology Companies (2022-2030) ($MN)
  • Table 41 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biopharmaceutical Companies (2022-2030) ($MN)
  • Table 42 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 43 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2022-2030) ($MN)
  • Table 44 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Product (2022-2030) ($MN)
  • Table 45 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biosimilars (2022-2030) ($MN)
  • Table 46 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics (2022-2030) ($MN)
  • Table 47 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Antisense and Molecular Therapy (2022-2030) ($MN)
  • Table 48 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Recombinant Proteins (2022-2030) ($MN)
  • Table 49 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Vaccines (2022-2030) ($MN)
  • Table 50 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Monoclonal (2022-2030) ($MN)
  • Table 51 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other Products (2022-2030) ($MN)
  • Table 52 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service (2022-2030) ($MN)
  • Table 53 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Manufacturing Organization (CMO) (2022-2030) ($MN)
  • Table 54 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Research Organization (CRO) (2022-2030) ($MN)
  • Table 55 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Type (2022-2030) ($MN)
  • Table 56 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Mammalian (2022-2030) ($MN)
  • Table 57 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Non-Mammalian (Microbial) (2022-2030) ($MN)
  • Table 58 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Viral Vector (2022-2030) ($MN)
  • Table 59 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 60 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2022-2030) ($MN)
  • Table 61 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biotechnology Companies (2022-2030) ($MN)
  • Table 62 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biopharmaceutical Companies (2022-2030) ($MN)
  • Table 63 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 64 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2022-2030) ($MN)
  • Table 65 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Product (2022-2030) ($MN)
  • Table 66 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biosimilars (2022-2030) ($MN)
  • Table 67 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics (2022-2030) ($MN)
  • Table 68 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Antisense and Molecular Therapy (2022-2030) ($MN)
  • Table 69 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Recombinant Proteins (2022-2030) ($MN)
  • Table 70 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Vaccines (2022-2030) ($MN)
  • Table 71 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Monoclonal (2022-2030) ($MN)
  • Table 72 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other Products (2022-2030) ($MN)
  • Table 73 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service (2022-2030) ($MN)
  • Table 74 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Manufacturing Organization (CMO) (2022-2030) ($MN)
  • Table 75 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Research Organization (CRO) (2022-2030) ($MN)
  • Table 76 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Type (2022-2030) ($MN)
  • Table 77 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Mammalian (2022-2030) ($MN)
  • Table 78 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Non-Mammalian (Microbial) (2022-2030) ($MN)
  • Table 79 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Viral Vector (2022-2030) ($MN)
  • Table 80 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 81 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2022-2030) ($MN)
  • Table 82 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biotechnology Companies (2022-2030) ($MN)
  • Table 83 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biopharmaceutical Companies (2022-2030) ($MN)
  • Table 84 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 85 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2022-2030) ($MN)
  • Table 86 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Product (2022-2030) ($MN)
  • Table 87 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biosimilars (2022-2030) ($MN)
  • Table 88 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics (2022-2030) ($MN)
  • Table 89 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Antisense and Molecular Therapy (2022-2030) ($MN)
  • Table 90 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Recombinant Proteins (2022-2030) ($MN)
  • Table 91 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Vaccines (2022-2030) ($MN)
  • Table 92 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Monoclonal (2022-2030) ($MN)
  • Table 93 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other Products (2022-2030) ($MN)
  • Table 94 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service (2022-2030) ($MN)
  • Table 95 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Manufacturing Organization (CMO) (2022-2030) ($MN)
  • Table 96 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Research Organization (CRO) (2022-2030) ($MN)
  • Table 97 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Type (2022-2030) ($MN)
  • Table 98 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Mammalian (2022-2030) ($MN)
  • Table 99 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Non-Mammalian (Microbial) (2022-2030) ($MN)
  • Table 100 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Viral Vector (2022-2030) ($MN)
  • Table 101 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 102 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2022-2030) ($MN)
  • Table 103 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biotechnology Companies (2022-2030) ($MN)
  • Table 104 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biopharmaceutical Companies (2022-2030) ($MN)
  • Table 105 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 106 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2022-2030) ($MN)
  • Table 107 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Product (2022-2030) ($MN)
  • Table 108 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biosimilars (2022-2030) ($MN)
  • Table 109 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics (2022-2030) ($MN)
  • Table 110 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Antisense and Molecular Therapy (2022-2030) ($MN)
  • Table 111 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Recombinant Proteins (2022-2030) ($MN)
  • Table 112 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Vaccines (2022-2030) ($MN)
  • Table 113 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Monoclonal (2022-2030) ($MN)
  • Table 114 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other Products (2022-2030) ($MN)
  • Table 115 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service (2022-2030) ($MN)
  • Table 116 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Manufacturing Organization (CMO) (2022-2030) ($MN)
  • Table 117 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Research Organization (CRO) (2022-2030) ($MN)
  • Table 118 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Type (2022-2030) ($MN)
  • Table 119 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Mammalian (2022-2030) ($MN)
  • Table 120 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Non-Mammalian (Microbial) (2022-2030) ($MN)
  • Table 121 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Viral Vector (2022-2030) ($MN)
  • Table 122 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 123 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2022-2030) ($MN)
  • Table 124 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biotechnology Companies (2022-2030) ($MN)
  • Table 125 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biopharmaceutical Companies (2022-2030) ($MN)
  • Table 126 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Other End Users (2022-2030) ($MN)